IMATINIB 400 MG — DIN 02521210
IMATINIB (IMATINIB MESYLATE) : 400 MG · SIVEM PHARMACEUTICALS ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is IMATINIB?
IMATINIB 400 MG contains IMATINIB (IMATINIB MESYLATE) : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02521210, held by SIVEM PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Imatinib cost around the world?
Imatinib is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 10 | 316 | AUD███.██ |
| Sweden | AIP (pharmacy purchase price) | 11 | 40 | SEK███.██ |
| United States | acquisition | 2 | 30 | USD███.██ |
| Hungary | producer price (ex-factory) | 15 | 18 | HUF███.██ |
| Greece | producer price (ex-factory) | 15 | 15 | EUR███.██ |
| Romania | max producer price | 7 | 13 | RON███.██ |
| Italy | prezzo al pubblico (classe A) | 7 | 12 | EUR███.██ |
| Slovakia | categorised final price | 10 | 10 | EUR███.██ |
| South Africa | single exit price | 7 | 8 | ZAR███.██ |
| Morocco | PPV (public price) | 3 | 6 | MAD███.██ |
| Iceland | max wholesale | 2 | 4 | ISK███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
478 pack listings across 94 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Imatinib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Imatinib in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Imatinib, across 27 DINs, of which 16 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CANADA INC | 3 | 2 | GLEEVEC | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 2 | 2 | ACH-IMATINIB | Sourceable in Canada |
| APOTEX INC | 2 | 2 | APO-IMATINIB | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 2 | 2 | MINT-IMATINIB | Sourceable in Canada |
| NATCO PHARMA (CANADA) INC | 2 | 2 | NAT-IMATINIB | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 2 | IMATINIB | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 2 | 2 | IMATINIB | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | TEVA-IMATINIB | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 0 | JAMP IMATINIB | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-IMATINIB | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 2 | 0 | SANDOZ IMATINIB | No marketed DIN |
| SUN PHARMA CANADA INC | 2 | 0 | TARO-IMATINIB | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Imatinib |
|---|---|
| ATC code | L01EA01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02521210 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2521210 |
| Brand name | IMATINIB |
| Generic / active ingredient | IMATINIB (IMATINIB MESYLATE) : 400 MG |
| Market authorization holder | SIVEM PHARMACEUTICALS ULC |
| Health Canada schedule | Prescription |
| ATC code | L01EA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01EA |
| Current status | MARKETED |
| Status date | 29-Apr-2024 |
| Original market date | 2024-04-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Imatinib in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 22 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
16 of 27 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-IMATINIB | 100 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02490986 |
| ACH-IMATINIB | 400 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02490994 |
| APO-IMATINIB | 100 MG | TABLET | APOTEX INC | MARKETED | 02355337 |
| APO-IMATINIB | 400 MG | TABLET | APOTEX INC | MARKETED | 02355345 |
| GLEEVEC | 400 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02253283 |
| GLEEVEC | 100 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02253275 |
| IMATINIB | 100 MG | TABLET | SANIS HEALTH INC | MARKETED | 02504596 |
| IMATINIB | 100 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02521202 |
| IMATINIB | 400 MG | TABLET | SANIS HEALTH INC | MARKETED | 02504618 |
| MINT-IMATINIB | 400 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02492342 |
2 · Same class — other molecules in ATC L01EA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dasatinib | APO-DASATINIB · REDDY-DASATINIB · SPRYCEL · TARO-DASATINIB · +1 more | 28 | 28 | Yes |
| Imatinib | ACH-IMATINIB · APO-IMATINIB · GLEEVEC · IMATINIB · +8 more | 27 | 16 | Yes |
| Nilotinib | APO-NILOTINIB · REDDY-NILOTINIB · TASIGNA | 8 | 6 | Yes |
| Bosutinib | BOSULIF · REDDY-BOSUTINIB | 6 | 4 | Yes |
| Asciminib | SCEMBLIX | 2 | 2 | Yes |
| Ponatinib | ICLUSIG | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01EX | Avapritinib · Cabozantinib · Capivasertib · Capmatinib · Entrectinib · +17 more | 80 | 64 |
| L01EB | Afatinib · Dacomitinib · Erlotinib · Gefitinib · Lazertinib · +1 more | 40 | 23 |
| L01EF | Abemaciclib · Palbociclib · Ribociclib | 17 | 14 |
| L01ED | Alectinib · Brigatinib · Ceritinib · Crizotinib · Lorlatinib | 10 | 10 |
| L01EJ | Fedratinib · Momelotinib · Ruxolitinib | 8 | 8 |
| L01EE | Binimetinib · Cobimetinib · Selumetinib · Trametinib | 8 | 7 |
| L01EN | Erdafitinib · Infigratinib · Pemigatinib | 11 | 6 |
| L01EC | Dabrafenib · Encorafenib · Vemurafenib | 5 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is IMATINIB called?
The same molecule, Imatinib, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Glivec | Latin | Australia, Morocco |
| Imatinib Sandoz | Latin | Australia, Sweden |
| ARX-IMATINIB | Latin | Australia |
| Gilmat | Latin | Australia |
| Imanib | Latin | Australia |
| IMATINIB RBX | Latin | Australia |
| IMATINIB-DRLA | Latin | Australia |
| Imatinib-Teva | Latin | Australia |
| Imatinib GH | Latin | Australia |
| Imatinib Accord | Latin | Iceland, Sweden |
| Imatab | Latin | Australia |
| Glivec® | Latin | Sweden |
| Imatinib Krka d.d. | Latin | Iceland, Sweden |
| Bimatix | Latin | Sweden |
| Imatinib Zentiva | Latin | Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.